Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delphine Rea

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
Hemasphere|November 16, 2020
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid LeukemiaDiletta Fontana, Daniele Ramazzotti, Andrea Aroldi, et al.
Cancer Cell|September 24, 2019
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 MutantsChristopher A Eide, Matthew S Zabriskie, Samantha L Savage Stevens, et al.
Blood|March 24, 2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trialJorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, et al.
Blood|October 26, 2014
Recurrent ETNK1 mutations in atypical chronic myeloid leukemiaCarlo B Gambacorti-Passerini, Carla Donadoni, Andrea Parmiani, et al.
Haematologica|May 26, 2022
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trialStéphanie Dulucq, Franck E Nicolini, Delphine Rea, et al.
Leukemia|March 23, 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy resultsMichael J Mauro, Timothy P Hughes, Dong-Wook Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2019
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML PatientsFranck Emmanuel Nicolini, Stéphanie Dulucq, Lisa Boureau, et al.
The New England Journal of Medicine|December 12, 2019
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P Hughes, Michael J Mauro, Jorge E Cortes, et al.
Leukemia|July 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemiaJane F Apperley, Dragana Milojkovic, Nicholas C P Cross, et al.
Cancer Cell|August 19, 2014
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemiaMatthew S Zabriskie, Christopher A Eide, Srinivas K Tantravahi, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Hemasphere|November 16, 2020
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid LeukemiaDiletta Fontana, Daniele Ramazzotti, Andrea Aroldi, et al.
Cancer Cell|September 24, 2019
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 MutantsChristopher A Eide, Matthew S Zabriskie, Samantha L Savage Stevens, et al.
Blood|March 24, 2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trialJorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, et al.
Blood|October 26, 2014
Recurrent ETNK1 mutations in atypical chronic myeloid leukemiaCarlo B Gambacorti-Passerini, Carla Donadoni, Andrea Parmiani, et al.
Haematologica|May 26, 2022
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trialStéphanie Dulucq, Franck E Nicolini, Delphine Rea, et al.
Leukemia|March 23, 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy resultsMichael J Mauro, Timothy P Hughes, Dong-Wook Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2019
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML PatientsFranck Emmanuel Nicolini, Stéphanie Dulucq, Lisa Boureau, et al.
The New England Journal of Medicine|December 12, 2019
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P Hughes, Michael J Mauro, Jorge E Cortes, et al.
Leukemia|July 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemiaJane F Apperley, Dragana Milojkovic, Nicholas C P Cross, et al.
Cancer Cell|August 19, 2014
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemiaMatthew S Zabriskie, Christopher A Eide, Srinivas K Tantravahi, et al.
Pageof 11